मुख्य सामग्री पर जाएं
अनुवाद जारी है — आपकी भाषा का संस्करण तैयार होने तक यह सामग्री अंग्रेज़ी में दिखाई जा रही है।
चर्चाओं पर वापस जाएं

Trends in Buprenorphine and Methadone Dispensing Among Medicare Advantage and Commercial Enrollees, 2019-2024

Healthcare
United States
August 27, 2026 को शुरू किया गया

This study examined national trends in methadone and buprenorphine dispensing among Medicare Advantage and commercial enrollees with opioid use disorder from 2019 to 2024, characterizing differences by insurance type, age, and dual eligibility

स्रोत लेख

कथन जोड़ें विश्लेषण 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
10 मतदान के लिए कथन • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (10+ recommended) 10/10
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM द्वारा पोस्ट admin • Aug 27, 2026
Access to both buprenorphine and methadone should be expanded for all enrollees to address opioid use disorder effectively.

अनुवाद लंबित है

Vote options for this statement: agree, disagree, or unsure
💬 चर्चा देखें
Be first to respond
Vote to see results
CLAIM द्वारा पोस्ट admin • Aug 27, 2026
The age demographic of enrollees significantly influences the type of opioid treatment they receive.

अनुवाद लंबित है

Vote options for this statement: agree, disagree, or unsure
💬 चर्चा देखें
Be first to respond
Vote to see results
CLAIM द्वारा पोस्ट admin • Aug 27, 2026
Buprenorphine dispensing among Medicare Advantage enrollees has significantly increased from 2019 to 2024.

अनुवाद लंबित है

Vote options for this statement: agree, disagree, or unsure
💬 चर्चा देखें
Be first to respond
Vote to see results
CLAIM द्वारा पोस्ट admin • Aug 27, 2026
Dual-eligible individuals have the highest rates of buprenorphine dispensing compared to other groups.

अनुवाद लंबित है

Vote options for this statement: agree, disagree, or unsure
💬 चर्चा देखें
Be first to respond
Vote to see results
CLAIM द्वारा पोस्ट admin • Aug 27, 2026
Insurance type should not dictate the quality of care for individuals with opioid use disorder.

अनुवाद लंबित है

Vote options for this statement: agree, disagree, or unsure
💬 चर्चा देखें
Be first to respond
Vote to see results
CLAIM द्वारा पोस्ट admin • Aug 27, 2026
Methadone dispensing has declined sharply among commercial enrollees during the same period.

अनुवाद लंबित है

Vote options for this statement: agree, disagree, or unsure
💬 चर्चा देखें
Be first to respond
Vote to see results
CLAIM द्वारा पोस्ट admin • Aug 27, 2026
Regulatory barriers continue to hinder equitable access to methadone for those in need.

अनुवाद लंबित है

Vote options for this statement: agree, disagree, or unsure
💬 चर्चा देखें
Be first to respond
Vote to see results
CLAIM द्वारा पोस्ट admin • Aug 27, 2026
Both Medicare Advantage and commercial plans should collaborate to improve treatment accessibility for opioid use disorder.

अनुवाद लंबित है

Vote options for this statement: agree, disagree, or unsure
💬 चर्चा देखें
Be first to respond
Vote to see results
CLAIM द्वारा पोस्ट admin • Aug 27, 2026
The rise in buprenorphine use indicates a shift towards more effective treatment options for opioid use disorder.

अनुवाद लंबित है

Vote options for this statement: agree, disagree, or unsure
💬 चर्चा देखें
Be first to respond
Vote to see results
CLAIM द्वारा पोस्ट admin • Aug 27, 2026
Commercial enrollees experience barriers to accessing methadone treatment due to insurance restrictions.

अनुवाद लंबित है

Vote options for this statement: agree, disagree, or unsure
💬 चर्चा देखें
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us